HK Stock Market Move | MICOT PHARMA-B (02335) rose nearly 6% in the afternoon as its innovative drug XTL6001 took the international academic stage for the third time.

MICOT PHARMA-B (02335) rose nearly 6% in the afternoon, reaching a 5.94% increase as of the time of this report, priced at HK$32.12, with a trading volume of HK$12.67 million. In recent news, MICOT Pharmaceuticals' self-developed innovative drug XTL6001 for kidney disease research has been successfully selected for poster presentation at the American Society of Nephrology Kidney Week 2026. This marks the third time this year that research related to XTL6001 has entered an international top-tier academic exchange platform, following two posters at ADA 2026 and two oral presentations at EASD 2026, further solidifying its ongoing R&D direction in the fields of metabolism and kidney disease. It is noteworthy that the company recently announced that its self-developed injectable neuroprotective candidate drug MT200605 for treating acute ischemic stroke (AIS) has successfully met its primary research endpoint in the Phase II clinical trial. As a small molecule drug included in a national major science and technology project and awarded FDA orphan drug designation, MT200605 aims to address core pain points in domestic stroke treatment with its unique three-pathway mechanism covering the entire disease process, potentially filling the clinical gap for neuroprotective agents and reshaping the competitive landscape for innovative cardiovascular and cerebrovascular drugs.